



ASIAN CENTRE FOR LIVER DISEASES AND TRANSPLANTATION LIMITED

ABN 42 091 559 125

13 June 2011

ASX Online
Company Announcements Office
ASX Limited

ASX RELEASE – RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Asian Centre for Liver Diseases and Transplantation Limited (“ACLDT” or “the Company”) wishes to advise that Mr Hoong Kee Tang has resigned from the Board as Independent Non-Executive Director, effective immediately.

The Board thanks Mr Tang for his past contributions and wishes him well for his future activities.


DARIO NAZZARI
Company Secretary

About Asian Centre for Liver Diseases and Transplantation

Asian Centre for Liver Diseases & Transplantation Ltd (ASX:AJJ), founded in 1994, started trading on the Australian Securities Exchange in September 2009. The company’s centre at Gleneagles Hospital, Singapore, is the largest private liver transplant and liver disease treatment facility in Asia, treating people from throughout the world. AJJ is progressing plans to establish centers in Vietnam, Malaysia and China to meet the growing demand in emerging markets.

The incidence of liver cancer has doubled in the past two decades and continues to increase due to hepatitis B and hepatitis C, alcoholism and fatty liver disease. AJJ has specialist skill in liver transplants from live donors, such as relatives, as the liver is the only human organ that can regenerate.

For further information, please visit www.asianlivercentre.com.sg

Australia contact:

Mr. Dario Nazzari, Company Secretary

Tel: +61 8 81100999

dario@uhyhn.com.au

Singapore contact (media):

WeR1 Consultants Pte Ltd

Tel : +65 6737 4844

maybarza@wer1.net